Remission and survival following monthly intraarterial cisplatinum in nonresectable hepatoma
Remission and survival following monthly intraarterial cisplatinum in nonresectable hepatoma
复制标题
DOI：
10.1081/cnv-120002486
复制
发表时间：
2002-01-01
影响因子：
2.4
通讯作者：
Zeiger, LS
中科院分区：
文献类型：
--
作者：
Court, WS;Order, SE;Zeiger, LS
PRECIS：对于不能切除的肝癌患者来说，每月动脉内注射顺铂50 mg/m(2)是一种耐受性良好的方案。顺铂在动脉内的选择性摄取表明，其他选择性动脉内化疗方案将适用于用顺铂治疗的区域癌症。背景：67例不能切除的肝癌患者每月接受50 mg/m(2)顺铂的肝动脉灌注(HAI)治疗。方法：48例患者接受全肝外照射，静脉注射顺铂50 mg/m(2)。19例患者未接受放射治疗，仅接受HAI顺铂治疗。所有患者随后每月接受HAI顺铂50 mg/m(2)治疗。6例患者被给予示踪剂量的195M顺铂，通过HAI和IV途径进行定量。结果：每月HAI顺铂耐受性良好，可无限期重复。初次治疗的不可切除肝癌的中位生存期为12个月[甲胎蛋白(AFP)升高]和17.5个月(AFP阴性)。HAI给予的放射性顺铂产生34-55%的肿瘤对顺铂的摄取。
Precis: Intraarterial delivery of 50 mg/m(2) cisplatinum on a monthly basis is a well-tolerated regimen for patients with nonresectable hepatoma. The selective uptake of cisplatinum delivered intraarterially suggests other selective intraarterial protocols would be of use in regional cancers treated with cisplatinum.Background: Sixty-seven patients with nonresectable hepatoma were treated with hepatic artery infusions (HAI) of 50 mg/m(2) cisplatinum on a monthly basis.Methods: Forty-eight patients received an initial course of whole liver external radiation with intravenous (IV) cisplatinum 50 mg/m(2). Nineteen patients did not receive radiation and received HAI cisplatinum only. All patients then received HAI cisplatinum at 50 mg/m(2) on a monthly basis. Six patients were given a tracer dose of radioactive (195m)cisplatinum for quantitation by the HAI and IV routes.Results: Monthly HAI cisplatinum was well tolerated and could be repeated indefinitely. Median survival for primarily treated nonresectable hepatomas was 12 months [alpha fetoprotein (AFP) elevated] and 17.5 months (AFP negative). Radioactive cisplatinum given by HAI yielded 34-55% tumor uptake of cisplatinum vs.